Navigation Links
Determining genetic signature of lung tumors can help guide treatment
Date:5/20/2008

The first U.S. clinical trial using genetic screening to identify lung tumors likely to respond to targeted therapies supports the use of those drugs as first-line treatment rather than after standard chemotherapy has failed. While the study led by Massachusetts General Hospital Cancer Center investigators found that upfront gefitinib (Iressa) treatment considerably improved the outcomes for non-small-cell-lung-cancer (NSCLC), additional research is required before such a strategy can be used for routine treatment planning. The report appears in the May 20 Journal of Clinical Oncology.

This is a pivotal clinical trial that demonstrates the power of personalized medicine in lung cancer treatment, says Lecia Sequist, MD, MPH, of the MGH Cancer Center, who led the study. It is an exciting glimpse into what we hope is the future of cancer care. Instead of a one size fits all therapy, we are moving towards finding the best treatment for each patient.

The most common form of lung cancer, NSCLC is the leading cause of cancer deaths in the U.S. Until recently, there were no treatment options for NSCLC patients in whom chemotherapy failed. Iressa, which disables the epidermal growth factor receptor (EGFR) on the surface of lung cancer cells, was approved in 2003 for treatment of NSCLC even though it shrank tumors in less than 15 percent of patients because, in those whom it did help, responses were rapid and dramatic.

In 2004 MGH Cancer Center researchers and a team from Dana-Farber Cancer Institute both discovered why Iressas success was confined to a limited group of patients. Specific EGFR mutations that were probably responsible for a tumors development also made the cancer sensitive to Iressa treatment. Subsequent to that announcement, the Laboratory for Molecular Medicine at the Harvard-Partners Center for Genetics and Genomics developed a test to screen for these sensitizing mutations.

Late in 2004 a collaborative gr
'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer
2. New method proposed for determining which patients should get treatment for colorectal cancer
3. CSHL scientists make progress in determining how the brain selectively interprets sound
4. NEJM Report Finds HPV Test More Effective Than Pap in Determining Cervical Cancer Risk
5. Will lung cancer recur? A genetic test may provide the answer
6. Genetic loci assigned for musical aptitude in Finnish families
7. Geneticists at the American Museum of Natural History trace the evolution of St. Louis encephalitis
8. Genetic links to impaired social behavior in autism
9. Genetic Engineering and Biotechnology News reports on early ADMET use
10. Combined physical and genetic map finds cancers ignition key
11. Research program focuses on genetic mutations and cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VA (PRWEB) , ... July 30, 2015 , ... ... introduction of the ‘Mary Jo Lawyer-Spano Mesothelioma Patient Registry Act of 2015’. ... Schakowsky (D-IL), Chris Collins (R-NY), Peter King (R-NY), Betty McCollum (D-MN), Joe Kennedy ...
(Date:7/30/2015)... ... 30, 2015 , ... Boston Web Marketing is ... Google Partners is the platform for search marketing agencies to communicate with the ... necessary to run successful search marketing campaigns. Google Partners also affords businesses the ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Ocean Hills ... available, including the very rare “no recommendations.” No recommendations means CARF found no areas ... is a notation that less than 3% of all facilities receive. In addition, Ocean ...
(Date:7/30/2015)... NY (PRWEB) , ... July 30, 2015 , ... ... at Mount Sinai Earns National Cancer Institute Designation , The Tisch Cancer Institute ... a National Cancer Institute (NCI)-designated cancer center. TCI joins an elite group of ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... 1Heart Caregiver ... 2015 - “Learn How to Make Money in the Booming Homecare Business.” This will ... CA 90010. , The event will be hosted by 1Heart’s very ...
Breaking Medicine News(10 mins):Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2
... SHANGHAI, China, Jan. 14 /PRNewswire-Asia-FirstCall/ -- China-Biotics, ... Company"), a leading Chinese firm,specializing in the ... products, today announced it has signed contracts,with ... Co., Ltd. ("Yuejia Food"),Shandong Huwa Dairy Industry ...
... Released as First Native ApplicationCHARLOTTESVILLE, Va., Jan. 14 ... a leader in knowledge management solutions for healthcare, ... download to Apple(R) iPhone(TM) and iPod(R) touch devices. ... for BlackBerry, Windows Mobile, and Palm OS devices ...
... 14 /PRNewswire/ -- Scarguard Labs, LLC, a ... and other dermatological problems through the use of multi-technology ... it has appointed Richard E. Pino as Chief Financial ... accounting, and treasury functions and will report to Chief ...
... Transfusion Service Software Confirms its Leading Position in ... Jan. 14 Global Med Technologies(R), Inc. ("Global ... an international e-Health, medical information technology company, today ... EgdeTrack* Transfusion Services Software (marketed as "Hemo Serveur" ...
... Number of people sickened in outbreak rises to 425 in ... -- As the number of people sickened by salmonella-contaminated peanut ... said Tuesday that one death in Minnesota and two in ... known for sure that the three people, whose names and ...
... Lagan, a provider of enterprise case management solutions that ... announced a new Lagan Human Services Call Center ... agencies in North America. The new solution is ... a range of functions depending on the programs administered, ...
Cached Medicine News:Health News:China-Biotics, Inc. Signs Agreements With Four Additional Food Manufacturers 2Health News:China-Biotics, Inc. Signs Agreements With Four Additional Food Manufacturers 3Health News:China-Biotics, Inc. Signs Agreements With Four Additional Food Manufacturers 4Health News:Unbound Medicine Announces Download Support for iPhone(TM) and iPod(R) Touch Devices 2Health News:Scarguard Labs, LLC Appoints Richard E. Pino as CFO 2Health News:Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 French Hospitals in 2008, Including 19 Hospitals in Q4 2008 2Health News:Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 French Hospitals in 2008, Including 19 Hospitals in Q4 2008 3Health News:Salmonella Linked to Deaths in Virginia, Minnesota 2Health News:Salmonella Linked to Deaths in Virginia, Minnesota 3Health News:Lagan Unveils Human Services Call Center Solution for North America 2
(Date:7/30/2015)... 30, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report its ... market close on Thursday, August 13, 2015, ... webcast at 4:30pm Eastern.Conference Call and Webcast:  ... Eastern/1:30pm Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... 2015 What can be expected ... are going to grow at the fastest rates? ... to 2025, assessing data, trends, opportunities and prospects there. ... tables, charts, and graphs. Discover the most lucrative areas ... new study lets you assess forecasted sales at overall ...
(Date:7/30/2015)... 2015  Cleave Biosciences today announced that the ... the company a key patent providing the protection ... This newly issued patent, "Fused pyrimidines ... 9,062,026, allows for claims on the composition of ... inhibitor of p97, a critical enzyme that controls ...
Breaking Medicine Technology:Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... 2012 Escalon Medical Corp.,s (Nasdaq Market: ESMC) subsidiary, ... successfully completed the outsourced manufacturing of its HbA1c instruments ... sale. Drew has also identified an outsourcing partner for ... available for sale by the summer of 2012.  Drew ...
... Pharmaceuticals, Inc. (Nasdaq: LXRX ) announced today ... and chief executive officer, will present at the RBC Healthcare ... 10:30 a.m. Eastern Time.  Dr. Sands will provide an overview ... A live webcast of the presentation will be available through ...
Cached Medicine Technology:Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 2Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 3Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 4Lexicon Pharmaceuticals to Present at the RBC Healthcare Conference 2
... The Elite II features ... proven University of Glasgow,(UG) algorithm. ... criteria to age, the UG,algorithm ... clinically,significant criteria: gender, age, race, ...
... face provides three contrast levels (high, 9.5 % ... 20/100. This test is designed to detect very ... contact lens evaluation or due to refractive surgery. ... the same contrast and acuity levels as the ...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
Medicine Products: